期刊
EXPERT REVIEW OF HEMATOLOGY
卷 15, 期 1, 页码 5-13出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/17474086.2022.2023007
关键词
Crizanlizumab; sickle cell disease; pain crisis; P-selectin; SEG101
类别
Crizanlizumab, a monoclonal antibody that blocks P-selectin, shows great promise in modulating the natural history of sickle cell disease with potential pleotropic effects. Ongoing studies aim to define its role in preventing other sickle cell-related complications, non-sickle cell inflammatory states, and thrombotic disorders.
Introduction P-selectin is a key adhesion molecule in the pathogenesis of sickle cell disease, including acute painful event(s). Many of the mediators activated in prototypical pain crisis are also involved in other complications seen in this population. Crizanlizumab is a monoclonal antibody approved in the US in 2019 for patients of all genotypes of sickle cell disease. By blocking P-selectin, it effectively prevents acute painful event(s) and has a manageable safety profile. Areas covered In this review, we provide an overview of the (i) biology of P-selectin in sickle cell disease, (ii) various agents inhibiting P-selectin, (iii) pharmacology of crizanlizumab, (iv) preclinical and clinical data on crizanlizumab, and (v) its potential for other indications, ongoing studies, regulatory status, and cost issues. Further, we describe its position among other approved agents in sickle cell disease and project future directions as well. Expert opinion Crizanlizumab holds great promise in modulating the natural history of sickle cell disease and may have pleotropic effects. Studies are ongoing to define its role in preventing other sickle cell-related complications, non-sickle cell inflammatory states, and thrombotic disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据